Baker et al. conducted two randomized, double-blind, placebo-controlled trials to assess the safety profile and metabolic effects of eptinezumab in 24 patients with obesity/overweight (study 1), assessed by changes in basal metabolic rate, as well as 21 patients with type 1 diabetes or T1D (study 2), assessed by insulin sensitivity in terms of body weight and insulin concentration corrected glucose infusion rate (M/I) [31]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.